Genome & Company (KOSDAQ:314130)
 2,910.00
 +55.00 (1.93%)
  At close: Oct 28, 2025
Genome & Company Revenue
Genome & Company had revenue of 5.81B KRW in the quarter ending June 30, 2025, a decrease of -50.04%. This brings the company's revenue in the last twelve months to 24.02B, up 0.39% year-over-year. In the year 2024, Genome & Company had annual revenue of 27.74B with 94.07% growth.
Revenue (ttm) 
 24.02B
Revenue Growth 
 +0.39%
P/S Ratio 
 4.16
Revenue / Employee 
 247.61M
Employees 
 97
Market Cap 
99.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 27.74B | 13.45B | 94.07% | 
| Dec 31, 2023 | 14.30B | 211.39M | 1.50% | 
| Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% | 
| Dec 31, 2021 | 451.25M | 300.66M | 199.67% | 
| Dec 31, 2020 | 150.58M | 104.75M | 228.54% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Electronics | 308.59T | 
| Hyundai Motor Company | 182.25T | 
| Kia Corporation | 111.04T | 
| SK hynix | 77.21T | 
| LG Energy Solution | 25.16T | 
| Hanwha Aerospace | 19.25T | 
| Doosan Enerbility | 16.30T | 
| HD Hyundai Heavy Industries | 15.58T |